# Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

> **NCT04941716** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Venetoclax
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT04941716
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-31
- **Primary completion:** 2027-08-10
- **Final completion:** 2031-08-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941716, "Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial". Retrieved via AI Analytics 2026-08-16 from https://api.ai-analytics.org/clinical/NCT04941716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*